Long term outcomes
Immediate and Long-term Outcomes
A synergistic effect is seen when VISCOSEAL® is administered with a local anaesthetic. Following arthroscopic shoulder surgery, 58 patients were given either 10 mL VISCOSEAL® plus 10 mL bupivacaine 0.5%, or 20 mL bupivacaine alone. Patients treated with VISCOSEAL® showed improved pain relief. Indeed, among 28 patients who received VISCOSEAL® plus bupivacaine following arthroscopic shoulder surgery, 29% reported no pain 4 h after the operation compared with 0% in the bupivacaine group.44
Following arthroscopy, pain relief was greater among patients who received VISCOSEAL® than among those who did not44
Reduced analgesia consumption
In the same study, at 4 h post-arthroscopy, 25% of patients who received VISCOSEAL® plus bupivacaine required no further analgesia, whereas all of the patients in the bupivacaine arm required some form of analgesia. Moreover, only 11% of patients treated with VISCOSEAL® plus bupivacaine required opiates compared with 33% of patients who received bupivacaine alone.44
Following arthroscopy, patients who received VISCOSEAL® required less analgesia than patients who received bupivacaine alone44
Reduced time to discharge from hospital
In addition to experiencing less pain, the 28 patients who received VISCOSEAL® plus bupivacaine were discharged in half the time taken to discharge those who received bupivacaine alone (5.2 vs 9.6 h; p =0.0001).44
Patients scheduled to undergo arthroscopy for degenerative osteoarthritis of the knee were randomised to VISCOSEAL® (n = 36) or standard treatment (n = 38).45 The relative benefit of VISCOSEAL® on pain when walking remained apparent 1 year after arthroscopy.
VISCOSEAL® reduced pain, when walking 100m, for at least 1 year after arthroscopy45
Patients in the VISCOSEAL® arm also gave superior ratings for clinical global impression compared with those in the standard treatment arm.
The percentage of patients who rated their global impression of treatment as 'clearly improved' or 'no complaints' was higher with VISCOSEAL® than with standard treatment45
The studies conducted with VISCOSEAL® have demonstrated the excellent safety profile of treatment. No adverse events relating to VISCOSEAL® have been reported in studies.41-45References